Patent Application
20180149626
This invention involves a novel analytical method for complete degradation products of low molecular weight heparin using hydrophilic interaction chromatography tandem multiple reaction monitoring mass spectrometry, which belongs to the technical areas of pharmaceutical, active pharmaceutical ingredients (API) and the detection technic of API.
Heparin and its derivatives, low molecular weight heparins (LMWHs) belong to one category of glycosaminoglycan (GAG). They are important anticoagulant drugs resulting from their anticoagulation functions. In order to reduce the risk of side effects, such as bleeding, osteoporosis, thrombocytopenia, and promote the bioavailability, LMWHs are widely utilized as new anticoagulant instead of heparin. LMWHs are manufactured by either enzymatical or chemical degradations making each kind of LMWH possessing its own special structures. Enoxaparin is a LMWH manufactured via alkaline depolymerization of benzyl ester of heparin. Its major non-reducing ends (NREs) are unsaturated uronic acid residues after chemical modification, while saturated uronic acid and amino sugar residues from the parent heparin are also existed. The major reducing ends (RE) are amino sugars which containing 15-25% of 1,6-anhydro structure, also there are a small amount of uronic acid residues and linkage region at the RE. Dalteparin is a kind of LMWH manufactured via nitrous acid degradation. Its major NREs are saturated uronic acid residues, while major REs is mannitol and a small amount of linkage region. In addition to these special ending structures, the backbone also varies during the manufacturing. All above make the analysis of complete degradation products of LMWHs a big challenge. Usually, there are two strategies for heparin analysis, top-down and bottom-up. Bottom-up analysis is the first choice for degradation product analysis. Heparin products generally enzymatically degraded to complete degradation products, and then are analyzed by capillary electrophoresis, high performance liquid chromatography (HPLC) and HPLC tandem mass spectrometry. These conventional methods were mainly focus on the 8 natural disaccharides and only a part of the special structures, not one can perform a comprehensive identification and quantitation analysis on complete degradation products derived from LMWHs. Take enoxaparin for instance, the original ending structures are not able to identified as the newly generated ending structures of building blocks during enzymatic digestion are identical to the original ones. However, these special structures with extremely low content usually contain important structural information related to the quality and safety of drugs. In other words, the characterization of these building blocks are essential.
In addition to the 8 natural disaccharides, the complete degradation products consist of 3-O-sulfated tetrasaccharides which related to the anticoagulation function, trisaccharides generated by peeling reaction, saturated NREs from parent heparin, N-unsubstituted disaccharides and galacturonic acid disaccharides from chemical modification and C-sulfated disaccharide and epoxide structures from molecular rearrangement. Moreover, there are some characteristic structures for different LMWHs, for example, 1,6-anhydro structures in enoxaparin and its original NRE and RE structures, 2,5-anhydro mannitol. No reported methods are able to cover all these building blocks, nevertheless, the analysis of these ending structures and special structures are indispensable for development of LMWH generic drugs, production control and safety control. Moreover, as some of the original ending structures, like enoxaparin, are identical to that of newly generated ending structures after enzymatical digestion, conventional samples preparation strategies are not capable for comprehensive characterization of enoxaparin.
Aiming at the shortcomings of current analytical techniques for LMWHs, this invention provides a comprehensive identification and quantitation analysis on complete degradation products derived from LMWHs using hydrophilic interaction chromatography (HILIC) tandem multiple reaction monitoring (MRM) mass spectrometry (MS).
This invention is able to distinguish the original NRE and RE structures of LMWH via performing a reduction reaction of the REs of LMWH and degrading the LMWH using hydrogen peroxide. The quantification of all building blocks is achieved by the separation on a HILIC and detected by a MRM tandem MS, especially for the special structures with extremely low relative contents. This new method is applicable to comprehensive characterization of LMWHs.
The procedure of this novel analytical method for complete degradation products of low molecular weight heparin using hydrophilic interaction chromatography tandem multiple reaction monitoring mass spectrometry is as follows:
1. Mobile phase A (MPA) is 3 to 10 mM of ammonium acetate in DI water.
2. Mobile phase B (MPB) is 3 to 10 mM of ammonium acetate in 90 to 98% acetonitrile.
3. For the LMWH that needs to distinguish the original ending structures, 10 to 50 μg LMWH sample with internal standard needs to be reducted with sodium borohydride first and hydrolysis using hydrogen peroxide. The dried hydrolysis product is prepared into solutions with the concentration of 1 to 10 μg/μL and go straight to step 4. For those LMWHs do not need to distinguish the original ending structures, 10 to 50 μg dried heparinase digested LMWH sample with internal standard are prepared into solutions with the concentration of 1 to 10 μg/μL for step 4.
4. Solutions prepared in step 3 are centrifuged prior to separation on HILIC column and detection on MRM tandem MS. The flow rate is 0.1 to 0.5 mL/min, and elution gradient are as follows, 0-5 min, 5% MPA, 95% MPB; 5-107 min, 5-23% MPA, 95-77% MPB; 107-112 min, 23-50% MPA, 77-50% MPB; 112-125 min, 50% MPA, 50% MPB;
5. The MRM tandem MS is performed under positive or negative ionization mode on a triple quadrupole MS. The parameters are set as follows, spry voltage under positive ionization mode is +4.0 kV, spry voltage under negative ionization mode is −3.2 kV, the sheath gas flow is 20-30 arb, tube lens voltage is ±50-150 V, collision energy is 20-50.
According to the present invention, heparinase digested LMWH sample with internal standard is dried under vacuum decompression dry for 1 to 3 hours at 30 to 60° C. in step 3.
According to the present invention, the centrifugation condition in step 4 is 10,000 to 15,000 rpm for 5 to 15 min at room temperature. Then further optimized to be 12,000 rpm for 15 min at room temperature.
This invention is capable to comprehensively identify all basic building blocks, not only including the 8 natural heparin disaccharides, but also all reported structures and some new structures. The usage of internal standard helps to relatively quantify all building blocks identified, successfully settled the drawbacks of conventional method. This invention possesses great practical value in LMWH generic drug development, production control and safety control.
Further restrictions will be defined by the figures attached combining with the examples below, but not limited as these.
The examples were performed on an Agilent 1100 series HPLC with a ChemStation workstation online coupling to a Thermo TSQ Quantum Ultra triple quadrupole MS with a Xcalibur workstation.
The procedure of this novel analytical method for complete degradation products of low molecular weight heparin using hydrophilic interaction chromatography tandem multiple reaction monitoring mass spectrometry is as follows:
1. Mobile phase A (MPA) is 5 mM of ammonium acetate in DI water.
2. Mobile phase B (MPB) is 5 mM of ammonium acetate in 95% acetonitrile.
3. Enoxaparin reference standard was enzymatically digested by heparinase I, II and III at 25° C. for 48 h, and internal standard was added before ultrafiltration using a 30 KDa molecular weight cut off membrane. The digests were vacuum decompression dried. The dried digests is prepared into solutions with the concentration of 10 μg/μL and go to step 5.
4. 50 μg enoxaparin sample with internal standard was reducted with sodium borohydride for 12 h first and hydrolysis using hydrogen peroxide. The dried hydrolysis product is prepared into solutions with the concentration of 10 μg/μL and go to step 5.
5. Solutions prepared in step 3 are centrifuged prior to separation on HILIC column with a particle size of 200 Å (2.0 mm×150 mm) and detection on MRM tandem MS. The flow rate is 0.1 to 0.5 mL/min, and elution gradient are as follows, 0-5 min, 5% MPA, 95% MPB; 5-107 min, 5-23% MPA, 95-77% MPB; 107-112 min, 23-50% MPA, 77-50% MPB; 112-125 min, 50% MPA, 50% MPB;
6. The MRM is performed on a Thermo TSQ Quantum Ultra triple quadrupole MS under negative ionization mode on a triple quadrupole MS. The parameters are set as follows, spry voltage under negative ionization mode is −3.2 kV, the sheath gas flow is 20-30 arb, tube lens voltage is ±75 V, collision energy is 35.
7. The concentration (c) of each component can be calculated according to the formula below, c=cIP×(A/AIP), cIP is the concentration of internal standard, A is the area of internal standard and the AIP is the area of this component.
8. The composition analysis of all identified building blocks were performed, the results for building blocks derived via enzymatic digestion are listed in table 1, the results for building blocks derived via chemical degradation are listed in table 2.
The extracted ion chromatography of building blocks derived via enzymatic digestion are shown in
The procedure of this novel analytical method for complete degradation products of low molecular weight heparin using hydrophilic interaction chromatography tandem multiple reaction monitoring mass spectrometry is as follows:
1. Mobile phase A (MPA) is 5 mM of ammonium acetate in DI water.
2. Mobile phase B (MPB) is 5 mM of ammonium acetate in 95% acetonitrile.
3. Dalteparin reference standard was enzymatically digested by heparinase I, II and III at 25° C. for 48 h, and internal standard was added before ultrafiltration using a 30 KDa molecular weight cut off membrane. The digests were vacuum decompression dried.
4. The dried digests is prepared into solutions with the concentration of 10 μg/μL and go to step 5.
5. Solutions prepared in step 3 are centrifuged prior to separation on HILIC column with a particle size of 200 Å (2.0 mm×150 mm) and detection on MRM tandem MS. The flow rate is 0.1 to 0.5 mL/min, and elution gradient are as follows, 0-5 min, 5% MPA, 95% MPB; 5-107 min, 5-23% MPA, 95-77% MPB; 107-112 min, 23-50% MPA, 77-50% MPB; 112-125 min, 50% MPA, 50% MPB;
6. The MRM is performed on a Thermo TSQ Quantum Ultra triple quadrupole MS under negative ionization mode on a triple quadrupole MS. The parameters are set as follows, spry voltage under negative ionization mode is −3.2 kV, the sheath gas flow is 20-30 arb, tube lens voltage is ±75 V, collision energy is 35.
7. The concentration (c) of each component can be calculated according to the formula below, c=cIP×(A/AIP), cIP is the concentration of internal standard, A is the area of internal standard and the AIP is the area of this component.
8. The composition analysis of all identified building blocks were performed, the results for building blocks derived via enzymatic digestion are listed in table 3.
The extracted ion chromatography of building blocks derived via enzymatic digestion are shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 201610330158.4 | May 2016 | CN | national |
This application is the U.S. national phase of International Application No. PCT/CN2017/074966 filed on 27 Feb. 2017 which designated the U.S. and claims priority to Chinese Application No. CN2016103301584 filed on 18 May 2016, the entire contents of each of which are hereby incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2017/074966 | 2/27/2017 | WO | 00 |
